Dr. Uribe is Chief of the Division of Spinal Problems, Volker Okay. H. Sonntag Chair of Backbone Analysis, and Vice Chairman of Neurosurgery at Barrow Neurological Institute
Dr. Uribe Turns into Aclarion’s 3rd KOL With Entry to a Diagnostic Middle Licensed to Carry out Nociscans
BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) — by way of NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the placement of continual low again ache, introduced at present that Nociscan is now accessible within the better Phoenix, AZ market on the Barrow Neurological Institute with Dr. Juan Uribe and different space physicians treating continual low again ache.
Dr. Uribe’s follow emphasizes a complete method to treating the spine and making use of minimally invasive spine surgical procedure to advanced degenerative illness. “I’ve devoted my life to assuaging the ache and struggling related to spinal issues. Low again ache is an especially debilitating situation that lacks a noninvasive device serving to me establish the placement of a affected person’s ache. I’m happy Nociscan is now accessible within the better Phoenix market, which can assist us proceed to advance extra correct analysis and coverings for low again ache,” mentioned Dr. Uribe.
Power low again ache (cLBP) is a number one reason for opioid dependancy within the U.S. and the one costliest analysis in the USA. Aclarion’s Nociscan answer is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives important insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
“Dr. Uribe is a famend neurosurgeon at one of many world’s main neurological institutes, Barrow,” mentioned Ryan Bond, Chief Technique Officer of Aclarion. “All through Dr. Uribe’s profession he has rejected norms and superior the therapy of continual low again ache by analysis, schooling and adopting innovation. We’re happy that he and the medical neighborhood in Phoenix will now have entry to Nociscan.”
Aclarion lately introduced the completion of the 1,000th business Nociscan examination and pointed to extra KOLs having access to MRIs as a key catalyst for supporting scan quantity development in 2024. Activation of the Phoenix market represents the primary such key catalyst of 2024.
For details about Nociscan use in Phoenix, please contact Aclarion at information@aclarion.com.
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives important insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch incorporates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, equivalent to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to plenty of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Change Fee. Readers are inspired to overview the part titled “Danger Elements” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Change Fee on April 25, 2022 beneath Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post